A case of tongue cancer developing in a 33-year-old man 7 years and 7 months after allogenic bone mallow transplantation (BMT) for acute myeloid leukemia is presented. The patient received chemotherapy and total body irradiation of a total dose of 12 Gy in a conditioning regimen. He was affected with chronic graft-versus-host disease after BMT, but had not complained of symptom in the oral cavity. Oral examination showed an ulcerative mass with induration at the right lateral border of the tongue. The mass was diagnosed as a squamous cell carcinoma by biopsy. The tumour was surgically removed. There was no evidence of recurrence or metastasis 9 months after surgery. The necessity of long-term follow-up of the oral cavity in recipients undergoing BMT is emphasized.
Introduction
Bone marrow transplantation (BMT) has become an essential part of the treatment for many cases of malignant and nonmalignant hematological disorders, but it is still associated with a wide range of complications. Among the complications following BMT, graft versus host disease (GVHD) is the most important and frequent. The development of secondary malignancies is also reported as one of the complications, and these secondary malignancies are classified into three categories: hematologic malignancies, lymphoproliferative disorders, and solid tumours. The first two are relatively frequent and usually occur soon after transplant, whereas the last is less common and the risk seems to increase over time. [1] [2] [3] [4] Overall, the risk of incidence of secondary solid tumour in patients undergoing BMT is reported to be two to three times greater than in the general population. 5 About one-third of all secondary solid tumours are skin and mucosal cancers, with squamous cell carcinoma (SCC) representing 50% of these cases. 1, [3] [4] [5] However, to our knowledge, only 13 cases of oral squamous cell carcinoma following BMT are reported. 3, [6] [7] [8] [9] [10] [11] [12] [13] [14] We present a new case of tongue SCC developing 7 years and 7 months after BMT. A 33-year-old man was referred to the Division of Oral and Maxillofacial Surgery, University of Tsukuba Hospital, from the Department of Hematology of the same hospital in June 2005, complaining of contact pain of the tongue. The patient had had acute myeloid leukemia diagnosed in December 1996, when he was 26 years old, and he underwent a BMT from his HLA-identical mother in November 1997, following a conditioning regimen that consisted of chemotherapy (2 days of cyclophosphamide at 3600 mg/day and 2 days of etoposide at 1200 mg/day), and total body irradiation (TBI; total dose of 12 Gy with multiple fractions). After the BMT, the recipient was treated with cyclosporin A at 5 mg/kg for 7 months as immunosuppressive therapy. He was affected with acute graft-versus-host disease (GVHD) in the skin and liver after the BMT, which subsequently became chronic GVHD, which eventually resolved 10 months after BMT. The patient had no oral symptoms during the time he had acute and chronic GVHD, but it was unclear from his records whether or not oral pathologies were present during this time. The patient has received neither immunosuppressive drugs nor medications after the completion of the administration of cyclosporine. He had abandoned smoking and alcohol consumption with 5 years duration before the BMT.
Oral examination showed an ulcerative mass with induration, measuring 21 · 18 mm, at the right lateral border of the tongue (Fig. 1 ). Lichen planus-like lesions were not observed in the oral or perioral tissues, and his oral hygiene condition was good and well-maintained. There was no clinical lymphadenopathy suspected of being metastasis in the neck. T2-weighted magnetic resonance images depicted a well-demarcated mass with high intensity at the right edge of the tongue (Fig. 2) .
A biopsy specimen revealed keratinization and cordlike clusters of alveolar tumour cells infiltrating the muscular layers, indicating a diagnosis of well-differentiated SCC (Fig. 3 ). The patient underwent partial glossectomy, and skin grafting for the defect in the resected tongue under general anesthesia. The surgical margins of the excised specimen were histologically free of tumour cells. The postoperative course was uneventful, and as of his most recent follow-up examination, 9 months after the surgery, there has been no evidence of recurrence or distant metastasis.
Discussion
The improvement in the survival rate of BMT patients has resulted in an increased incidence of long-tem complications, including the development of secondary malignant solid tumours. 5 One of the most common sites of solid cancers in these recipients is reported to be an oral cavity, 1,5 and many of these oral cancers has been histologically diagnosed as SCC. Although oral SCC is considered to be frequent as secondary solid tumour in BMT recipients, there were only 13 reported cases of oral SCC following BMT in the literature. 3, [6] [7] [8] [9] [10] [11] [12] [13] [14] The 13 cases consisted of seven males and six females, with an age range from 12 to 53 years, and a mean age of 28.2 years. The tumours arose predominately in the tongue and infrequently in the buccal mucosa, gingiva, and floor of the mouth. The duration between BMT and the detection of oral cancer ranged from 5 to 11 years, with a mean of 7.9 years. Surgeries were performed for the oral cancers in all but two cases, for which the treatment modality was not reported. Ten of 13 reported cases had chronic GVHD (Table 1) . As described by Demarosi et al., this small sample series suggests that patients affected with oral secondary cancer after BMT tend to be male and are younger than oral cancer patients in the general population, where the tumour is predominant in male and uncommon among young adults. 4 Several potential risk factors for secondary solid cancer following BMT have been previously noted. The cytotoxic therapy of the conditioning regimen, consisting of chemotherapeutic agents and irradiation, has been suggested as the primary risk factor, because this regimen could induce gene mutations and enhance the risk of malignant transformation of cells. 4, 15, 16 Chronic GVHD may be predisposing factor, because oral SCC was reported to develop at the site of a previous chronic GVHD lesion in many of the reported cases. Stimulation of the oral mucosa by GVHD may therefore be associated with the development of cancers. 1, 2, 4, 5, 10, 17 Prolonged use of immunosuppressive drugs allows the malignant transformation of cells, 3, 4, 18 as well as the growth of genetically abnormal cells which is normally controlled by the immune system, so the post-BMT treatment may be a risk factor. A significant relationship was found between patient age at the time of BMT and the risk of solid cancer: there is an increased risk of developing secondary tumours after BMT in patients under 30 years old, 1,4 so age is considered as a significant risk factor. The fact that 8 of the 13 reported cases were in patients under 30 years old supports this hypothesis. As other risk factors, human papilloma virus infection, a primary diagnosis of hematological disorders, and type of transplant have been described. 4 The increased use of BMT treatment and better survival of the recipients after BMT are anticipated in future. Oral secondary cancers have the potential to occur in BMT recipients many years after BMT, so the necessity of long-term follow-up of the patients is emphasized to detect cancers early. In addition, BMT patients should be informed of high potential cancer risk and encouraged to adopt a preventive life style, avoiding risk factors such as smoking, alcohol consumption, and poor oral hygiene. 
